Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + BR in First-Line CLL
NCT01980888Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Feb 2014; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01980888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01980888.